The production of retroviral vectors showing pronounced biological and physicochemical stability is essential for their application in human gene therapy. Biological instability of mouse retroviruses in human sera is mainly caused by complement reaction with a specific part of the retroviral transmembrane protein and the presence of Gal(␣1-3)Gal carbohydrates on the envelope glycoprotein eliciting an immune response by respective antibody circulating in the human blood stream. On the contrary, the phenomenon of physicochemical instability is far less understood. Retroviruses are considered to be unstable particles in a technical sense. Envelope shedding, viral enzyme sensitivity, and degradation by extracellular proteases are regarded as reasons for the limited lifespan of released retroviruses. To investigate whether the nature of the packaging cell line influences the technical properties, we have generated amphotropic mouse retroviral vectors carrying green fluorescent protein, ␤-galactosidase, and selection marker genes from producer cell lines originating from different species (mouse, hamster, and human). We compared their storage properties and temperature sensitivity using titration assays on indicator cell lines, real-time reverse transcriptase (RT)-polymerase chain reaction (PCR) for detection of RT activity, and a real-time PCR test able to estimate nucleic acid content in mouse retroviral particles. We found that storage temperatures influenced the retroviral stability derived from NIH3T3, BHK-A, BHK-B, and TE671 cells in a different manner. Surprisingly, the type of amphotropic env as well as the temperature during the production phase affected retroviral half-lives in the cellular supernatants. The ratio of nucleic acid containing viral particles/infectious virus particles varied considerably in retrovirus populations from individual cell lines, indicating pronounced differences in the quality of retrovirus production in these cell types. Real-time RT-PCR showed that RT activity in virions is only marginally affected by the conditions of storage or production. Therefore, the equipment of retroviruses with structural proteins or cellular parameters (protein processing, glycosylation, lipid composition of the plasma membrane) may account for the differences observed. Currently, the findings are subject to further investigations.
The production of retroviral vectors showing pronounced biological and physicochemical stability is essential for their application in human gene therapy. Biological instability of mouse retroviruses in human sera is mainly caused by complement reaction with a specific part of the retroviral transmembrane protein and the presence of Gal(␣1-3)Gal carbohydrates on the envelope glycoprotein eliciting an immune response by respective antibody circulating in the human blood stream. On the contrary, the phenomenon of physicochemical instability is far less understood. Retroviruses are considered to be unstable particles in a technical sense. Envelope shedding, viral enzyme sensitivity, and degradation by extracellular proteases are regarded as reasons for the limited lifespan of released retroviruses. To investigate whether the nature of the packaging cell line influences the technical properties, we have generated amphotropic mouse retroviral vectors carrying green fluorescent protein, ␤-galactosidase, and selection marker genes from producer cell lines originating from different species (mouse, hamster, and human). We compared their storage properties and temperature sensitivity using titration assays on indicator cell lines, real-time reverse transcriptase (RT)-polymerase chain reaction (PCR) for detection of RT activity, and a real-time PCR test able to estimate nucleic acid content in mouse retroviral particles. We found that storage temperatures influenced the retroviral stability derived from NIH3T3, BHK-A, BHK-B, and TE671 cells in a different manner. Surprisingly, the type of amphotropic env as well as the temperature during the production phase affected retroviral half-lives in the cellular supernatants. The ratio of nucleic acid containing viral particles/infectious virus particles varied considerably in retrovirus populations from individual cell lines, indicating pronounced differences in the quality of retrovirus production in these cell types. Real-time RT-PCR showed that RT activity in virions is only marginally affected by the conditions of storage or production. Therefore, the equipment of retroviruses with structural proteins or cellular parameters (protein processing, glycosylation, lipid composition of the plasma membrane) may account for the differences observed. Currently, the findings are subject to further investigations. Developing expression vectors for high levels of gene expression is important in both molecular biology and gene therapy. This is especially relevant in the field of immune gene therapy, because the antitumoral effects of cytokines such as interleukin-2 (IL-2) and interferon-␥ are dose-dependant and a critical "threshold" level must be reached for successful therapy. Our laboratory has approached this problem by creating new sets of expression vectors using the amplifier strategy. The amplifiers consist of a constitutive, inducible, or tissue-specific promoter controlling the expression of a transcription factor that trans-activates a second promoter(s) located on the same construct. The second promoter(s) drives the gene(s) of interest. Two of our new amplifier expression vectors, pHi-1-MCS and pHi-2-MCS, use the HIV 1 and HIV 2 long terminal repeats (LTRs) to drive the gene inserted in the multiple cloning site. Both vectors also contain a cytomegalovirus (CMV) promoter-controlled tat gene, which is a trans-activator of the HIV LTRs. Using the human IL-2 gene as the reporter/ therapeutic gene, we have shown that pHi-1-IL-2 and pHi-2-IL-2 produced 17.2 and 48.1-fold more secreted IL-2 than the CMV promoter in the human breast carcinoma cell line MCF-7. The relative fold increase for pHi-1-IL-2 and pHi-2-IL-2 is 6.8-fold and 12.5-fold in the human lung cancer cell line A549 and 6.5-fold and 9.0-fold in human forskin fibroblasts. In addition, pHi-1-IL-2 and pHi-2-IL-2 are 5.3-fold and 9.6-fold stronger than the CMV promoter in the mouse melanoma cell line B-16. The higher levels of IL-2 expression appear to be due to greater amounts of IL-2 produced per cell, because these vectors have similar transfection efficiencies. In the mouse tumor models B16 (melanoma), 4T1 (breast), and LL2 (lung), injection of tumor cells transfected with pHi-2-IL-2 leads to slower tumor growth and longer survival than either wild-type tumors or tumor cells transfected with pCMV-IL-2. These studies suggest that the amplifier concept may be important in developing future high level gene therapy vectors.
strate deoxyribonucleoside kinase of Drosophila melanogaster (Dm-dNK) and shown that the enzymes phosphorylates both pyrimidine and purine nucleoside analogs as well as several clinical important nucleoside analogs. The broad substrate specificity of this enzyme, together with a high catalytic rate, makes it a unique member of the nucleoside kinase enzyme family. In the present study, we have constructed a retroviral vector that expressed the Dm-dNK cDNA and used the vector to transduce human cancer cell lines. We found that the cells expressing Dm-dNK exhibited an increase in sensitivity to several cytotoxic nucleoside analogs. These data show that the multisubstrate nucleoside kinase of D. melanogaster is a candidate suicide gene for further development of combined gene therapy/chemotherapy of malignant tumors. Local production of therapeutic proteins via gene therapy (e.g., for cancer treatments) requires tight spatial and temporal controls. Local hyperthermia of varying intensity and duration was tested as a noninvasive signal to control the expression of a transgene under the control of the thermo-inducible hsp70 promoter. The characterization of the time-temperature heat shock conditions and of time of recovery for efficient transgene expression was realized using a stably transfected glioma C6 cell line expressing the enhanced green fluorescent protein (EGFP) reporter gene under the control of the heat-inducible minimal hsp70 promoter, both in vitro and in vivo. A heat shock of 20 -30 minutes at 43°C in cell culture led to a maximum EGFP concentration at ϳ24 hours. Treatment at higher temperature (up to 48°C) with shorter duration (down to 30 seconds) also induced strong EGFP expression.
Local heating in situ, using water flowing through a needle traversing a transfected subcutaneous C6 mouse tumor, led to EGFP expression decreasing with increasing distance to the heat source. Focused ultrasound (FUS) with a wavelength of ϳ1 mm is capable of noninvasively depositing energy in a target area deep within the body without harming neighboring tissues. Continuous mapping of temperature was achieved noninvasively using magnetic resonance imaging and was used for feedback-controlled FUS heating of a subcutaneously implanted tumor. The results demonstrated increased levels of EGFP in the heated region. This approach shows the feasibility of spatial and temporal control of transgene expression.
Helper-dependent herpes simplex virus (HSV) vectors (commonly known as HSV amplicons) are able to transfer genes into both dividing and quiescent cells, and thus have the potential to be widely used as vectors in physiological studies and gene therapy. Historically, these vectors were produced by superinfection with a helper virus that furnished all the trans-acting functions required for amplification and packaging into HSV-1 particles. In these systems, however, large amounts of potentially harmful helper virus are present in the vector stocks produced, thus restricting the use of these vectors. In the past few years, new helper virus-free packaging systems have been developed that utilize transfection of helper functions rather than infection and thus produce safer vector stocks. However, the vector titers obtained with these systems have been quite low. We present here a novel system for producing high-titer amplicon vector with low contamination by helper viruses. This system is based on the use of the Cre-loxP recombination system, which allows efficient deletion of the packaging signal of an HSV-1 recombinant helper virus (HSV-1-LaL) on Cre-expressing cells (TE-CRE30). These conditions supply all of the trans functions required for the production of a high titer of amplicon vector (10 7 UI/mL before concentration, with Ͻ0.01% contamination by the LaL helper virus). This system presents the advantages of being easy to manipulate and inexpensive; in addition, it allows reamplification of vector stocks by successive passages on TE-CRE30 cells. Methods by which the safety of this system can be further improved are also presented.
The vpr gene is found in HIV-1, HIV-2, and simian immunodeficiency virus and encodes the 15-kDa viral protein R (Vpr), which is produced late in the virus life cycle and is assembled into the virion through binding to Gag. It is known to bind RNA and DNA and may therefore be an integral component of the preintegration complex after reverse transcription. The presence of Vpr has been shown to facilitate nuclear import of the complex, possibly through interactions with karyopherins. Considering these properties, we have explored the possibility of using Vpr directly as a DNA transfection agent.
First, we analyzed the DNA binding activity of a variety of synthetic Vpr-derived peptides in gel retardation assays. Our study shows that peptides from the C-terminal domain (residues 52-96) but not from the N-terminus (residues 1-51) are able to complex DNA. Transfection experiments identified two peptides (Vpr52-96 and Vpr52-93) as agents with higher efficiencies (up to 500-fold) than polylysine on 293 cells. Surprisingly, the full-length Vpr was always significantly less efficient than polylysine in these experiments.
Our study of the intracellular fate of Vpr52-96/DNA complexes indicates that only a minority of these complexes efficiently find their way to the nucleus; most are trapped in vesicles or in the cytosol and are quickly degraded. The active fraction of complexes ending up in the nucleus either avoids the endocytic route or can be released from endosomes following a pH-independent mechanism. We are currently performing experiments to determine whether Vpr52-96 facilitates the nuclear import of pDNA.
To our knowledge, Vpr52-96 represents a unique example of a natural peptide that is able to bind DNA and transport it into cells as efficiently as transfection agents such as
In contrast to murine leukemia viruses (MLVs), lentiviruses such as HIV-1 are able to infect various nonproliferating cell types. However, although retroviral vectors derived from HIV-1 seem to exhibit the same biological properties as wild-type (wt) HIV-1, allowing integration of the transgene in the nonproliferating target cells, some particular quiescent cell types that are essential gene therapy targets are poorly transduced by such vectors. In the case of primary T lymphocytes, completion of reverse transcription and subsequent integration of the lentivirus genome does not occur efficiently unless the cells have been activated by using either anti-CD3 and anti-CD28 antibodies or mitogenic factors.
We have recently demonstrated an alternative strategy for the stable transduction of quiescent cells by engineering MLV envelope glycoproteins that display growth factor polypeptides. We have reported the construction of a chimeric MLV retroviral envelope glycoprotein containing interleukin-2 (IL-2). Retroviral vector particles that incorporate such chimeric envelope glycoproteins onto their surface can stimulate IL-2 receptors (IL-2R) on the target cell surface, inducing transient proliferation of the target cells at the time of gene delivery. The IL-2 chimeric envelopes were coexpressed in MLV retroviral vector particles with wt envelopes to allow infection to proceed through the natural retroviral receptor. IL-2R-expressing target cells were transiently activated when they were incubated with retroviral vectors displaying the IL-2 chimeric envelope glycoprotein. Moreover, the IL-2R-positive target cells were transduced at a 34-fold higher efficiency by vectors pseudotyped with the IL-2 chimeric envelope than by vectors carrying wt amphotropic envelopes.
These results encouraged us to develop HIV-1-derived lentiviral vectors expressing such activating chimeric envelopes for T-lymphocyte transduction. Here we report the characterization of HIV-1 vectors that incorporate MLV-derived envelope glycoproteins that display IL-2 or anti-CD3 single-chain antibody. These chimeric envelopes, correctly expressed onto the HIV-1 vector surface, were functional for cell activation and enhancement transduction in human primary T lymphocytes. We discuss the usefulness of such chimeric envelopes according to the activation state of the target T lymphocytes.
Cantharidin, extracted from blister beetles, is one of the natural products used in Chinese herbal medicine to treat human and animal tumors. However, use of cantharidin is limited due to its severe toxicity for mucous membranes, mainly in the gastrointestinal tract, ureter, and kidney. Norcantharidin, the demethylated analog of cantharidin, has less nephrotoxic and inflammatory side effects.
p53 has been shown to play a role in regulating cellular survival after DNA damage. Exogenous expression of p53 has also been shown to induce chemosensitivity and radiation sensitivity in some human tumors. Previously, we have shown that norcantharidin induces apoptosis more efficiently in cell lines with endogenous wild-type (wt) p53. Cell lines with mutant p53 were more resistant to norcantharidin treatment. In this report, we investigated whether overexpression of wt p53 through adenoviral gene delivery induced malignant brain tumor chemosensitivity to norcantharidin.
High-titer p53/EGFP adenovirus was used to infect several glioblastoma cell lines with endogenous mutant p53. More than 90% of the tumor cells expressed p53/EGFP fusion protein after adenovirus infection at 100 multiplicities of infection. Flow cytometry analysis showed high percentages of tumor cells undergoing apoptosis after p53/EGFP gene insertions and norcantharidin treatment compared with p53/EGFP insertions, norcantharidin treatment, and controls.
The dosage of norcantharidin required to induce ID 50 in glioblastoma cells after adenoviral-mediated p53/ EGFP transgene expression was found to be 100 times less compared with controls. p53/EGFP gene delivery into in vivo glioblastomas also required less norcantharidin dosage to achieve tumor suppression. These results showed adenoviral-mediated p53/EGFP into glioblastomas with endogenous mutant p53 genotype enhanced chemosensitivity to norcantharidin. Combination gene therapy using p53 tumor suppressor gene and Chinese herbal medicine may provide an alternative way to treat chemoresistant malignant brain tumors.
Abstract 9
Targeted gene delivery to HER-2 overexpressed cells by immunolipoplex The field of nonviral gene delivery was significantly advanced by using cationic liposomes. Basically, the delivery vehicle was formed by complexing cationic lipids with plasmid DNA (lipoplex). Previously, we have shown that N- (1-[2,3-dioleoyloxy] propyl)-N,N,N-trimethylammonium methylsulfate (DOTAP)/cholesterol lipoplex remained stable for months, in addition to reproducible high transfection efficiency in vivo after intravenous injections.
In this report, we further developed a targeted gene delivery system aimed at HER2-overexpressed breast cancers (SKBR3 cell line) by adding anti-HER2 antibody (Ab) to the lipoplex. The modified anti-HER2 Ab (FabÍ) was added to DOTAP/cholesterol using conjugated maleimido-PEG2000-DOPE. This specific modification constricted the sizes of the immunoliposomes to Ͻ1 m in diameter (0.5 Ϯ 0.2 m) and remained stable for long duration of time (5 hours) compared with lipoplex controls (2 m Ϯ 1.2 m, 2 hours). In addition, a 2-to 10-fold increase in luciferase activity was achieved after transfecting SK-BR3 breast cancer cells with anti-HER2-conjugated DOTAP/cholesterol immunolipoplex compared with DOTAP/cholesterol lipoplex. A total of 87% of SKBR3 cells were shown to express green fluorescent protein activity 72 hours after anti-HER2-conjugated DOTAP/cholesterol immunolipoplex transfection (85 Ϯ 12%) compared with DOTAP/cholesterol lipoplex (55 Ϯ 8%) and pCMV-EGFP plasmid transfection (2 Ϯ 0.5%) by flow cytometry analysis.
These results demonstrated highly efficient targetspecific gene delivery to the HER2-overexpressed breast cancer cell line SK-BR3 using anti-HER2 Ab-conjugated DOTAP/cholesterol. The implications of these results were further discussed. The generation of delivery vectors that are both safe and efficient has become potentially the greatest (major) challenge to a successful use in cancer gene therapy. The objective of this study was to determine the efficacy of a cationic lipid, bis-guanidium-tren-cholesterol (BGTC), for the delivery of double suicide gene into a peritoneal disseminated pancreatic tumor. Carcinoembryonic antigen (CEA)-positive human pancreatic tumor cells (BxPc3 cells) were injected intraperitoneally (i.p.) in athymic mice. At J8, animals were injected by the same route with either naked DNA (herpes simplex virusthymidine kinase (HSV-tk)/Escherichia coli-CD) or DNA lipid (BGTC) complex. After 2 days, half of each experimental group received a daily i.p. injection of ganciclovir (GCV) and 5-fluorocytosine (5-FC) for 12 days. The gene transfer efficiency of BGTC was studied using the reporter genes pCMV-Luc and pCMV-GFP. The efficiency of HSV-tk/E. coli-CD gene expression on pancreatic tumor cell growth was estimated by reverse transcriptase-polymerase chain reaction (RT-PCR), by enzyme-linked immunosorbent assays of the CEA serum concentration, and by survival follow up of mice. When the complex BGTC/DNA was used, reporter gene activities were strongly enhanced and RT-PCRs of gene transcripts were positive. CEA secretion was reduced significantly when prodrugs were injected. In this experimental design, the survival rate was not significantly improved, despite longer survival in some animals (two of eight mice at J65) treated with BGTC/DNA complex and prodrugs. Thus, these results indicate that the use of double suicide genes (HSV-tk/GCV and E. coli-CD/5-FC) is a potent modality for the treatment of peritoneal carcinosis; in addition, these findings suggest that this cationic lipid (BGTC) might be a promising vector for gene transfer and should be explored further.
Abstract 10

Abstract 11
Occurrence, in an HIV-1 lai -infected promonocytic U937 cell line, of a long readthrough transcript with an HIV long terminal repeat followed by 3.7-kb of cellular DNA sequences Results: During the course of this mRNA display, we characterized in infected U937 cells a 3.7-kb readthrough transcript with a long terminal repeat (LTR) located 5Ј upstream to cellular sequences. Sequencing analysis revealed that cellular sequences of this chimeric transcript contain two alu sequences (superfamily J), with one being surrounded by two mammalian-wide interspersed repeat element (MIRs). A small potential open reading frame (ORF) was detected near the 3Ј extremity of the mRNA encoding for 89 amino acid residues (estimated molecular mass of 9.5 kDa) with no significant homology to any known protein.
Discussion: Cis-transcriptional activation of cellular DNA sequences downstream from a retroviral LTR is a molecular event that is of major importance and has been shown to be critical in the ontogenesis of oncogenic retroviruses. Swain and Coffin were able to demonstrate that readthrough transcript, in the case of avian leukosis virus, might be the first step toward the transduction of cellular sequences. In the case of HIV infection, Raineri et al have shown that readthrough transcripts can occur in vivo in seropositive patients. Furthermore, Shiramizu et al found a common clonal HIV integration site in HIV virus-associated lymphomas. These authors were able to detect the insertional cis-activation of the protooncogene c-fes in AIDS-associated lymphomagenesis. Indeed, our finding represents additional data that confirm that the occurrence of readthrough transcripts constitutes a potential deleterious effect of retroviral LTR integration. Such powerful promoter activity should not be underestimated in the design of retroviral vectors.
Abstract 12
Tissue-specific, cell cycle-regulated chimeric transcription factors for the targeting of gene expression to tumor cells Recently designed approaches for cancer gene therapy include the use of vectors that direct the tumor-specific expression of enzymes converting prodrugs into toxic metabolites. A prerequisite for such an approach is the availability of tools that allow for either tumor-specific delivery or tumor-specific expression of the effector gene. Because tumor-specific promoters are rare, the latter can be achieved by using tissue-specific promoters to drive the effector gene. Such an approach will, however, also lead to expression in normal cells of the same lineage. Therefore, we sought to combine tissuespecific expression with an additional regulatory mechanism by which expression can be limited to the tumor. The effector gene product could then activate a cell cycle-independent drug that acts extracellularly or is transmitted to other cells. This approach should thus lead to the destruction not only of the expressing tumor cell but also of all adjacent cells irrespective of their proliferative activity. To this end, we have established a general approach (dual-specificity chimeric transcription factor (DCTF) system) for the construction of dualspecificity promoters combining tissue specificity and cell cycle regulation. The gene of interest, whose expression is to be restricted to proliferating cells of a specific tissue type, is driven by an artificial heterodimeric transcription factor, whose DNA-binding subunit is expressed by a tissue-specific promoter, whereas the transactivating subunit is driven by a cell cycle-regulated promoter.
We show that expression of a luciferase reporter gene occurs preferentially in proliferating melanoma cells using a combination of the cyclin A promoter and elements of the tyrosinase promoter. Cell-type specificity was in the range of 55-fold when compared with cell lines derived from other tumor types, and the extent of cell cycle regulation was ϳ6-fold. At the same time, we were able to show by intratumoral injection that the cyclin A promoter is functional in vivo and gives rise to high levels of reporter gene activity.
The DCTF system should be widely applicable and also suitable for targeting disseminated tumor cells and micrometastases.
Abstract 13
Highly efficient gene delivery by mRNA electroporation for tumor antigen loading of dendritic cells The outcome of dendritic cell (DC)-based vaccines will highly depend upon the efficacy of the DC loading strategy. Transfection of DC with tumor antigens (Ags) using nonviral vectors provides many advantages over recombinant viruses, but the problem of inefficient gene expression remains. This is due in part to limited entry of DNA into the nucleus. Therefore, a cytoplasmic expression system based on electroporation of in vitro transcribed (IVT) mRNA was developed. In this study, we show that mRNA-based electroporation efficiently introduces tumor Ags into human DC. Preliminary experiments in K562 cells revealed that mRNA electroporation compared with cDNA electroporation showed a markedly improved transfection efficiency (85% versus 40% enhanced green fluorescent protein-positive cells) as well as a strikingly lower cell toxicity (15% versus 51%). High-level gene transfer by mRNA electroporation was obtained in all types of DC, particularly in monocyte (Mo)-derived DC (55 Ϯ 14%), because this DC type is difficult to transfect by conventional cDNA transfection methods (Ͻ5% efficiency). Importantly, DC electroporated with mRNA encoding Melan-A were superior to mRNA-lipofected and -pulsed DC as well as to plasmid cDNA-transfected DC for activation of an established Melan-A-specific cytotoxic T-lymphocyte (CTL) clone in an HLA-restricted manner. In addition, we observed nonspecific stimulation of CTL by plasmid cDNA-transfected DC. Optimal stimulation of the CTL clone occurred when DC underwent maturation after loading with mRNA. Our data clearly demonstrate that Mo-DC electroporated with mRNA present functional antigenic peptides to cytotoxic T cells in an efficient manner. Moreover, there was a good correlation between mRNA transfection efficiency and Ag loading efficiency in all types of DC. Therefore, mRNA-based electroporation provides a powerful tool to charge human DC with tumor-specific Ags in DC-based tumor vaccine settings. The PTEN gene, which is located at chromosome 10q23, was found to be mutated and/or deleted in many human advanced cancers. PTEN is a dual specificity phosphatase and functions as a PI3K antagonist. Recent studies have suggested that PI3K is involved in angiogenesis induction in human cancers. To determine whether the PTEN gene inhibits angiogenesis in lung cancers, PTEN was introduced into lung cancers using adenovirus. Reverse transcriptase-polymerase chain reaction and Western blot analysis showed high expression efficiency of PTEN-HA in lung cancer cell lines at 100 multiplicities of infection (MOI). Immunocytochemical staining with anti-HA antibody indicated that Ͼ90% of tumor cells expressed PTEN-HA at this MOI. In addition, PTEN-HA dephosphorylated phospho-AKT as efciently as wild-type PTEN. VEGF production was reduced after adeno-PTEN-HA infection in cell lines overexpressing activated PI3K, suggesting PTEN expression inhibited VEGF production by competing with PI3K activity.
Abstract 14
PTEN bystander effect in lung cancer is induced by angiogenesis inhibition
Adenoviral-mediated PTEN-HA (HA-tagged fulllength PTEN cDNA) gene delivery into several human lung cancers in vivo resulted in transgene expressions and in a significant bystander effect. This effect was found to inhibit angiogenesis. Microvascular density in maximal neovascularization areas was reduced by 80% after PTEN-HA expression compared with controls. A 65% reduction in tumor growth in vivo was also detected after PTEN gene delivery. These results showed that adenoviral-mediated PTEN gene insertions successfully inhibited lung cancer angiogenesis by down-regulating VEGF expression. This novel function of PTEN suggests that targeting PTEN signaling may yield a potentially effective therapeutic intervention for lung cancer.
Abstract 15
Adenovirus-mediated p16 gene transfer inhibits glioblastoma angiogenesis in vivo through down-regulation of VEGF Tumor suppressor gene may represent an important new therapeutic modality in the treatment of human glioblastoma.
Loss of p16 functions through deletion and/or mutation is a frequent event in the progression of gliomas. Angiogenesis, found prominently in high-grade gliomas, is induced by tumor-producing angiogenic-related factors such as VEGF. In this report, we evaluated p16 gene insertional effects in glioblastoma angiogenesis. High-titer adenovirus encoding full-length human p16 cDNA was used to infect p16-defective glioblastoma cell lines. P16 transgene expression decreased VEGF mRNA levels compared with controls, as assessed by reverse transcriptase-polymerase chain reaction analysis. VEGF protein levels were significantly reduced after p16 gene insertion compared with controls. In addition, p16 was found to down-regulate VEGF promoter activities in a transient cotransfection experiment using p16 expression plasmid and VEGF promoter green fluorescent protein reporter plasmid. Restoring p16 expression into glioblastoma cells in vivo markedly inhibited tumor angiogenesis. Intratumoral injections of p16 adenovirus further prolonged animal survival compared with controls. These findings indicate that p16 plays an important role in regulating glioblastoma angiogenesis, suggesting a novel therapeutic modality in the treatment of human glioblastoma.
Abstract 16
Multicistronic anti-angiogeneic retroviral vectors for the gene therapy of malignant brain tumors Glioblastoma multiforme are highly malignant brain tumors that cause death in a few months despite surgical removal and radiation. These tumors are among the most angiogenic of all tumors, with the amount of neovasculature closely related to the degree of malignancy. The growing body of evidence that selective inhibitors of angiogenesis can retard tumor growth in vivo led us to design retroviral vectors expressing antiangiogenic factors for the gene therapy of such tumors, which represent a privileged target, depicting an area of aggressively replicating cells in an otherwise almost totally quiescent tissue. Thus, with the aim of exploiting the retroviral peculiarity of infecting exclusively replicat-ing cells, we produced murine Moloney leukemia virusbased vectors encoding the N-terminal 16-kDa fragment of rat prolactin (16KrPRL) or human platelet factor 4 (PF4), two factors whose antiangiogenic action has already been demonstrated. We also produced "double" vectors, encoding contemporarily for two factors together, from a single retroviral promoter/enhancer (5Ј long terminal repeat), thanks to the insertion of an internal ribosome entry site between their two coding regions. We thus obtained high-titer retroviral producer cells (titer of Ͼ10 6 plaque-forming units/mL); their culture supernatants, containing 16KrPRL and/or PF4 encoding viruses, were used to transduce C6 rat glioblastoma cells in vitro, and polyclonal populations of cells were selected for puromycin resistance. Reverse transcriptase-polymerase chain reaction analysis revealed viral messages of anticipated sizes for 16KrPRL and PF4. The supernatants of these stably infected cell lines were tested in vitro for their ability to selectively inhibit the migration of endothelial cells in response to the proangiogenic stimuli normally contained in wild-type C6 supernatants. In fact, the presence of either of the two factors in cell supernatant drastically reduced (Ϫ45%) the C6 proangiogenic activity with regard to induction of endothelial cell migration; significantly, the coproduction of both factors together further reduced endothelial cell migration (Ϫ67%), suggesting that the two molecules might act in a cooperative way.
To further investigate the mechanisms underlying the antiangiogenic activity of 16KrPRL and PF4, we are now studying the possible inhibitory effects of these factors on different steps of endothelial cell recruitment and reorganization, such as proliferation of endothelial cells and/or invasiveness through the extracellular membrane. Moreover, we are constructing new retroviral vectors coexpressing more than two antiangiogenic factors, with the aim of developing more powerful tools against the proangiogenic potential of the growing tumoral mass and of eventually transferring the in vitro data to animal models (rat, mouse) of malignant brain tumors and antiangiogenic gene therapy. The ability of tumor cells to escape recognition and destruction by the immune system is believed to be critical for their growth and survival. Recent studies have demonstrated that a number of tumor cell lines express Fas ligand (FasL), and that this expression may facilitate the induction of apoptosis in host immune cells. In fact, previous work from our laboratory has shown that injection of the FasL-positive LSA tumor cell line into syngeneic mice led to significant levels of apoptosis in the thymus and spleen.
Abstract 17
Characterization of tumor-derived Fas ligand and its ability to induce apoptosis in immune cells of the host
The goal of the current study was to determine the phenotype of the cells undergoing apoptosis in the peripheral lymphoid organs. Injection of the LSA tumor led to significant induction of apoptosis in the spleen. Flow cytometric analysis of splenocytes from LSA-challenged mice revealed that apoptosis was induced in T cells (CD3 ϩ This work was supported in part by Grants ES09098, HL058644, and AI01392 from National Institutes of Health.
Abstract 18
Arsenic trioxide induces apoptosis in human colon cancer cell lines through caspase activation Failure to undergo apoptosis may be an underlying pathophysiological defect in human colorectal cancer. Arsenic trioxide and arsenic disulfide, two compounds used in traditional Chinese medicine, are very effective in acute promyelocytic leukemia (APL) treatment. More recently, in vitro studies using NB4 cells, an APL cell line with chromosome translocation t(15;17) from a relapsed APL patient, showed that arsenic trioxide induced apoptosis-associated down-regulation of the bcl2 gene, a well-known programmed cell death inhibitor. The aim of the present study was to investigate the effects of arsenic trioxide on cell proliferation and apoptosis induction in the human colon cancer originated cell lines HT29 and Colo320. Arsenic trioxide decreased cell growth and induced significant inhibition (Ͼ50%; P Ͻ .001) of Topoisomerases are essential nuclear enzymes involved in many aspects of DNA metabolism. Two major topoisomerases; type I and type II, have been identified in all eukaryotic cells. Proliferating cells exhibit a much higher enzyme contact and activity than cells that are quiescent or terminally differentiated. These enzymes are specific and sensitive markers for cell proliferation.
In the present study, we tested the effect of the topoisomerase-targeted drugs camptothecin and etoposide on cell proliferation of the human colon cancer cell line HT-29. Camptothecin and etoposide induced significant inhibition (Ͼ50%; P Ͻ .001) of [ Ϫ5 M etoposide or 10 Ϫ6 M camptothecin for 72 hours induced 55% and 68% apoptosis, respectively. Interestingly, exposure of Colo320, a human colon cancer originated cell line, to 10 Ϫ7 camptothecin or 10 Ϫ6 etoposide for 48 hours induced apoptosis associated with cell cycle arrest in G 2 phase. Cell death was inhibited by cyclohexamide, suggesting the requirement for new protein synthesis. The above study indicates that inhibition of topoisomerases in human colon cancer cell lines in vitro induced cell cycle arrest followed by apoptosis. This suggests that topoisomerases may be an important target of antitumoral drugs for tumors showing elevated levels of this enzyme. In addition, the phase of cell cycle arrest by the same drug is colon cancer cell line type-dependent.
Abstract 20
Plasmid-mediated delivery of interleukin-2, p53, and bax genes causes antitumoral effects in the C6 glioma model The use of interleukin-2 (IL-2) and tumor suppressor p53 for immunotherapy and gene therapy for cancer has shown promising results. Bax is a pro-apoptotic member of the bcl-2 gene family that control cell apoptosis. In this study, we examine the efficacy of plasmid gene therapy using murine IL-2, the wild-type (wt) human p53 gene, the combination of these genes, and the human bax gene, which are under the control of the cytomegalovirus (CMV) immediate-early promoter, in nude mice bearing established subcutaneous C6 glioma. In vitro enzyme-linked immunosorbent assay and immunocytochemical analysis for therapeutic genes demonstrated expression of the proteins in C6-transfected cells. In animal studies, nude mice were inoculated in the hind leg with 5 ϫ 10 5 viable C6 cells; established tumors were then injected three times (150 Ïg/injection) with pWS4 (control vector), pWS4-IL-2, pWS4-p53, pWS4-IL-2/ pWS4-p53, and pcDNA-bax. Significant antitumoral activity was observed for IL-2, for the IL-2 and p53 combination, and for the bax group (P Ͻ .002, .04, and .0007, respectively). However, no synergistic effect was observed in the p53/IL-2 combination group. No systematic differences in the proliferation of natural killer and B cells were observed among the animal groups, suggesting a local antitumoral effect of the plasmid gene therapy. Interestingly, bax gene treatment showed a significant reduction in tumor volume when compared with p53 treatment (P Ͻ .02). Thus, our in vivo studies demonstrate that delivery of naked therapeutic genes is safe, and results in reduction of tumor volumes in nude mice. needed. A novel gene (pHyde) was identified by an improved cDNA competition hybridization technique of rat Dunning prostate cancer cell lines. To characterize the biological function of pHyde, a replication-deficient recombinant adenovirus containing pHyde cDNA gene under the control of a truncated Rous sarcoma virus (RSV) promoter (AdRSVpHyde) was generated. In vitro, AdRSVpHyde significantly inhibited the growth of the human prostate cancer cell lines DU145 and LNCaP in culture. In vivo, a single injection of AdRSVpHyde at 5 ϫ 10 9 plaque-forming units reduced DU145 xenograft tumors growing in nude mice remarkably compared with untreated control-or viral control-treated DU145 tumors. In addition, AdRSVpHyde induced apoptosis and sensitized cells to ultraviolet irradiation apoptosis as indicated by DNA laddering and terminal deoxynucleotidyltransferase-mediated deoxyuridine triphosphate nick-end labeling staining assays. Moreover, AdRSVpHyde stimulated p53 expression in DU145 cells, implying that the p53 pathway may be involved in pHyde-mediated apoptosis. Taken together, these results suggest that pHyde is a tumor suppressor gene that inhibits growth by inducing apoptosis. Consequently, AdRSVpHyde should be considered in human clinical trials for prostate cancer gene therapy. The transfer of pro-apoptotic genes to tumors is one of the most promising strategies for anticancer gene therapy. However, the use of potentially toxic genes, such as tumor suppressor genes or apoptotic genes, needs controllable transgene activation. To achieve regulation of the transgene at a desired time, we developed an adenovirus (Ad) vector in which the apoptotic activity of the target gene has been made 4-hydroxy-tamoxifen (4-OHT)-dependent by fusion to the ligand-binding domain of the estrogen receptor (ER). For evaluation of the system in human tumor cells, we used the E2F1 gene, which encodes a transcription factor that triggers massive apoptosis in several human cancers. AdER-E2F1 expressed high levels of transgene over at least 1 week. Upon activation of E2F1 by the ligand 4-OHT, the ER-E2F1 fusion protein correctly translocated from the cytosol to the nucleus, transactivated E2F-dependent promoters, and rapidly induced substantial E2F1-related toxicity. Finally, experiments in nude mice showed tightly regulated tumor growth suppression in vivo. Taken together, our system represents a powerful approach for tight regulation and rapid induction of cytotoxicity as the major criteria for safe gene delivery.
Abstract 22
Regulation of adenoviral-delivered toxic genes by 4-hydroxy-tamoxifen (4-OHT) binding to the estrogen receptor for safe cancer gene therapy
This work was supported by Grant 10-1411 from the Deutsche Krebshilfe, by Mildred Scheel Stiftung (to B.M.P.), and by an IFORES doctoral fellowship from the University of Essen (to F.C.). To develop a pharmacogene therapy approach for neuroblastomas, we investigated the usefulness of two promoters for neuroblastoma-specific gene expression: the promoters for neuron-specific enolase (NSE) and tyrosine hydroxylase (TH), both representing clinically important tumor markers. We studied reporter gene expression by the two promoter fragments in transient transfection experiments using human and mouse neuroblastoma cell lines as well as fibroblasts and nonneuroectodermal tumor cell lines. We applied two different assays for these promoter studies: Fluorescenceactivated cell sorter analysis of specific enhanced green fluorescent protein (EGFP) expression and a dual luciferase assay with specific promoter-dependent firefly luciferase (lucϩ from Photinus pyralis) gene expression and constitutively expressed Renilla luciferase (from Renilla reniformis) as an internal control. For both assays, expression vectors with the two neuroblastomaspecific promoter fragments were constructed. The 308-bp rat NSE promoter fragment was cloned from plasmid pNSElacZ. A 523-bp fragment of the 5Јflanking region of the TH gene spanning from Ϫ486 to ϩ37 relative to the transcription initiation site was generated by polymerase chain reaction amplification from human genomic DNA. Both EGFP and lucϩ reporter gene assays revealed neuroblastoma-specific expression of the NSE and TH promoter fragments. The EGFP reporter gene systems were only applicable in highly transfectable cells, whereas the luciferase assays were feasible in all evaluated cell lines independent of transfection efficiency. Neuroblastoma-specific gene expression by the NSE promoter was significantly higher than expression by the TH promoter. In conclusion, both promoter fragments are promising tools for targeting therapeutic transgene expression to neuroblastoma cells. The NSE promoter fragment appears to be superior. Further experiments will be performed to show selective neuroblastoma cell killing after transduction with different vector systems containing the NSE or TH promoter to mediate herpes simplex virus thymidine kinase gene expression.
Abstract 23
Abstract 24
Impact of bladder cancer cell architecture on cytotoxic T-lymphocyte activation Immunotherapy of malignant human tumors has become a realistic option. Nevertheless, discrepancies persist between the immune responses to cancer cells observed either in vitro or in vivo in animal models and the antitumoral immune responses observed in vivo in clinical trials. A striking difference between in vitro models and in vivo conditions is the tumor architecture: most in vitro tests are performed on two-dimensional monolayer cancer cells, whereas tumor cells adopt a three-dimensional geometry in vivo.
Purpose: We investigated whether geometrical conformation may modulate T-cell activation that requires intimate target-effector contacts. To do so, we used the tumor spheroid model ,which represents quite realistically the three-dimensional growth and organization of avascular solid tumors and mimics more precisely the in vivo cell-to-cell interactions and microenvironment conditions in comparison with the standard monolayer model.
Materials and Methods:
We used two human bladder tumor cell lines (Tum 07 and Tum 24) and their autologous cytotoxic tumor-infiltrating lymphocyte (TIL) lines (TIL 07 and TIL 24) previously established in our laboratory. Tum 07 and Tum 24, cultured as either monolayers or spheroids, were used as targets in mixed lymphocyte reactions with TIL 07 and TIL 24, respectively. Activation of TIL was determined by measuring tumor necrosis factor release. Anti-CD3 immunostaining was performed in spheroids incubated with TIL to study T-cell infiltration into microtumors. Flow cytometric analyses allowed us to determine LFA-3, intercellular adhesion molecule-1 (ICAM-1), and HLA class I molecule expression by tumor cells in both conformations.
Results: Tumor architecture deeply influenced T-cell activation: two-dimensional monolayers of Tum 07 and Tum 24 cancer cells activated the TIL lines TIL 07 and TIL 24, respectively, whereas the capacity of the threedimensional spheroids Tum 07 and Tum 24 to activate autologous TIL was dramatically decreased. Interestingly, spheroids comprising 2 ϫ 10 3 cells kept a slight capacity of T-cell activation, whereas spheroids of higher volume (5 ϫ 10 3 cells) did not activate T cells. Moreover, we found that, at least in these two cell lines, the impact of cancer cell architecture was not due to: (a) lack of TIL infiltration into spheroids, (b) down-regulation of major histocompatibility complex class I molecules, and (c) implication of either costimulatory molecule B7.1 or adhesion molecules ICAM-1 and LFA-3.
Conclusions: Tumor architecture may have a deep impact on T-cell activation. These findings suggest that: (a) in vitro assays based on spheroids mimic the in vivo tumor geometry more closely than do standard monolayers. They might thus be useful for studying tumor response to immunotherapy, including gene therapy; (b) tumor architecture might represent an additional mechanism for human solid tumors to escape T-cell recognition.
Abstract 25
Expression of CD70 and CD80 by gene-modified tumor cells induces an antitumoral response depending upon the major histocompatibility complex (MHC) status The expression of costimulatory molecules such as CD80 by gene-modified tumor cells has been shown to enhance the antitumoral immune response based mainly on T lymphocytes. However, most human tumors show defects in major histocompatibility complex (MHC) expression, preventing them from being recognized by MHC-restricted T cells. To investigate whether coexpression of CD70 and CD80 costimulatory molecules induces comparable antitumoral responses in low and high MHC-expressing tumor cells, we used two low immunogenic murine tumor models, the B16.F10 melanoma and the TS/A mammary adenocarcinoma cell lines expressing, respectively, low and high levels of MHC class I molecules. Transfection of both CD70 and CD80 genes resulted in an increased capacity of gene-modified tumor cells to costimulate in vitro the proliferation and cytokine production of optimally activated lymphoid cells. Coexpression of CD70 and CD80 by the two tumor cell lines (TS/A and B16.F10) resulted in both cases in partial regression of subcutaneous tumors. Immunochemical analysis and studies in nude mice showed that, even in the B16.F10 model, T cells had a significant role in the antitumoral response induced by combining CD70 and CD80. However, rejection of the CD70/CD80-transfected tumor cells appeared to be more effective in the MHC class I high TS/A model, leading to a protection against parental tumor cells. B16.F10 and TS/A transfectants were then tested with fibroblasts genetically modified to secrete interleukin-12 (IL-12) as a therapeutic vaccine in mice bearing parental tumors. In the two models tested, the injections of irradiated IL-12 and CD70/CD80 gene-modified cells generated an antitumoral response to established tumors, leading to the slowing down of the tumor growth rate. Although the mechanisms remain to be defined, these findings suggest that the combination of several immunomodulatory molecules could provide additional strategies for cancer immunogene therapy, even for tumors deficient in MHC expression.
Abstract 26
Induction of specific antitumoral immunity with semiallogeneic and CD154-expressing tumor cell lines In an attempt to induce protective antitumoral immune responses able to avoid tumor escape mechanisms, we tested semi-allogeneic tumor cell lines genetically modified to express CD154 molecules. The presence of semi-allogeneic major histocompatibility complex (MHC) class I antigen should induce a strong nonspecific immune response, and the expression of CD154 costimulatory molecule on the tumor cells should enhance tumor-specific antigen presentation by dendritic cells. Two murine tumor models were used: the MHC class I-negative melanoma B16F10 and the MHC class I-positive mammary adenocarcinoma TS/A. B16F10 cells were transfected with H-2Dd and CD154 coding genes. Wild-type (wt) and modified melanoma cells (10 5 cells/mouse) were injected subcutaneously in syngeneic C57BL/6 mice (H-2b). These genetic modifications induced a reduction in vivo in the progression of the modified tumors (ϳ60% of the tumor surface) but also of the wt tumors injected on the contralateral flank (ϳ50% of the tumor surface). Splenic lymphocytes from tumor-bearing mice were able to inhibit in vitro tumor proliferation.
TS/A cells were transfected only with CD154 coding gene. TS/A cells were injected subcutaneously (10 5 cells/mouse) in H-2-compatible mice: B6D2 (H-2b*H2d). The expression of CD154 on modified tumor cells is sufficient to induce a significant reduction of wt tumor growth (ϳ60% of the tumor surface) and modified tumor growth (ϳ80% of the tumor surface). The protection against wt tumor progression is observed when wt tumors cells are injected mixed with the modified tumor cells or when they are injected in the opposite flank of the mouse.
Later, TS/A cells will be transfected with H-2Kk coding gene to render them semi-allogeneic to B6D2 mice.
We are currently analyzing the effector cells involved in tumor cell rejection and the specificity of the immune reaction induced. In the sera of mice bearing CD154-expressing tumors, significant amounts of interferon-␥ (ϳ300 g/mL) have been detected. This study could have implications in human tumor immunotherapy. Semi-allogeneic and CD154-expressing tumor cell lines could be used to stimulate patient's lymphocytes and lessen the need for an established autologous cell line.
Abstract 27
Study of CD8
؉ and CD4 ؉ T-cell responses against human chorionic gonadotropin ␤ subunit, a tumorassociated antigen The ␤ subunit of human chorionic gonadotropin (hCGb) is markedly up-regulated in tumor cells of differing histological origins, including bladder epithelium. In a previous study, we showed that some patients with hCGb-productive urothelial tumors had circulating T cells that proliferated specifically in response to hCGb. This suggested that a T-cell repertoire specific for this protein is present in healthy individuals.
To study the potential of hCGb as a target for cancer immunotherapy, we investigated whether hCGb-derived peptides induce T-cell responses in vitro and can be presented at the surface of bladder tumor cells. Two of six hCGb-derived peptides that exhibited HLA-A*0201 binding ability were able to stimulate CD8 ϩ cytotoxic T lymphocytes from two HLA-A*0201 unrelated naive subjects. The two immunogenic peptides correspond to regions hCGb(40 -48) and hCGb(75-84).
In addition, by stimulating peripheral blood mononuclear cells from a third subject with a mixture of 10 overlapping synthetic peptides representing region hCGb(20 -71), we established one CD4 ϩ T-cell line that proliferated specifically in response a single peptide, hCGb(52-67). Interestingly, this latter peptide contains several predicted HLA-DR binding motifs and could therefore behave like a promiscuous epitope. The processing and presentation of these three peptides by bladder tumor cell lines producing hCGb is currently under investigation.
Our results indicate that hCGb might be a target of both CD4
ϩ and CD8 ϩ immune responses and might thus be considered as a candidate antigen for antitumoral immunotherapy. Malignant melanoma (MM) is an immunogenic tumor. Despite the expression of major histocompatibility complex (MHC) class I and class II molecules on MM tumor cells and marked tumor infiltration of CD4 ϩ and CD8 ϩ T cells, the immune response is not potent enough to prevent lethal tumor progression. In the past, many efforts have been undertaken to enhance the antimelanoma immune responses by ectopically expressing immune accessory molecules in MM.
Abstract 28
Adenoviral expression of CD40-ligand (CD154) in malignant melanoma cells augments anti-melanoma T-cell responses: Implications for immunotherapy
In this study, we evaluated the effectiveness of CD40-ligand (CD40L) as a master immunomodulator to enhance MM immunogenicity. MM cells were genetically modified by infecting the cells with a replication-deficient adenoviral vector (AdV-CD40L) that encodes the recombinant murine CD40L molecule, also known as CD154. Stimulation of CD40 via CD40L interaction has been shown to be a very potent activator of antigenpresenting cells such as dendritic cells (DC) and B cells.
Primary melanoma tumor cells isolated from several MM patients were successfully infected with AdV-CD40L at a multiplicity of infection of 100. A high surface expression of CD40L at 48 hours postinfection was confirmed by fluorescence-activated cell sorter analysis. Upon coincubation with allogeneic as well as autologous T lymphocytes, CD40L-expressing MM cells induced significantly higher IFN-␥ production when compared with AdV-lacZ expressing or unmodified control cells. This effect was specific and could be blocked by anti-MHC class I and anti-CD40L antibodies. Furthermore, coincubation of CD40L-expressing MM cells with DC was shown to induce the secretion of interleukin-12, indicating DC activation. Future experiments will address whether the adenoviral expression of CD40L in MM will be sufficient to induce robust T-cell proliferation and stimulate an anti-melanoma cytolytic response. Taken together, this results of this study show a potent immunostimulatory role of CD40L that is capable of inducing an anti-melanoma immune response. We will further investigate the potency of AdV-CD40L treatment as a potential clinical immunotherapy for melanoma patients.
Abstract 29
Intraperitoneal gene therapy for desmoid disease in familial adenomatous polyposis Desmoid tumors are benign fibromatoses arising in musculoaponeurotic tissues. They can be aggressive in their infiltration and compression of surrounding structures, leading to considerable morbidity and even mortality.
Desmoid disease is unusual in the general population but is a well-recognized extra-intestinal manifestation of the premalignant condition familial adenomatous polyposis (FAP). Clinical desmoid disease affects up to 13% of patients with FAP, and subclinical disease may be present in a higher percentage. The majority of desmoids in FAP are intraabdominal (70%), and of these 80% arise in the small bowel mesentery. Now that individuals with FAP are routinely offered prophylactic colectomy (and endoscopic surveillance of the rectal stump and duodenum) to reduce the risk of malignancy within the gastrointestinal tract, desmoid disease has emerged as the most common overall cause of death in FAP, and tends to occur at a significantly younger age than death from other causes.
Desmoids are true neoplasms and appear to be clonal proliferations. In FAP, germline mutation or loss of the adenomatous polyposis coli (APC) gene predisposes individuals to their development. Somatic mutation or loss of the second allele of APC is detected in the majority of cases. At the moment, there is limited treatment and no prophylaxis available for desmoid disease. Surgery appears to aggravate the situation. Chemotherapy is minimally effective. Therefore, there is a need for minimally invasive, safe prophylaxis and/or treatment.
Object of Study: This study has looked at the feasibility of injecting additional copies of the normal human APC gene in the plasmid vector pCMV-APC-NeoBam directly into the peritoneal cavity in combination with liposomes to enhance tissue uptake of the gene.
Materials and Methods: Eight wild-type mice were treated in this manner; four controls were treated with Lipofectamine only. Two treated mice and one control animal were killed at daily intervals from 1 to 4 days. Samples of peritoneum, mesentery, liver, gonads, and small and large bowel were collected, snap-frozen, and examined for the presence of the transgene as mRNA, using techniques of RNA extraction and reverse transcriptase (RT)-polymerase chain reaction (PCR).
Results: The APC transgene was expressed as mRNA within the peritoneum of all of the animals treated with the plasmid; in addition, APC was expressed in the liver, mesentery, and gonads of seven, seven, and three of eight mice treated with plasmid, respectively.
None of the control animals were positive for the transgene mRNA in any samples, and no signal was generated from tissues in the absence of RT, thus ensuring that the PCR products were not derived directly from the exogenous plasmid, but from mRNA. There was no mortality, and no side effects were noted.
Conclusion: Lipofection (unlike viral gene therapy) appears to be safe, and we have shown here that it allows prolonged expression of the APC gene in the target tissues of the mesentery, peritoneum, and liver with minimal systemic effect on the host. The next step is to look at the clinical effect of this treatment in a murine model of desmoid disease in FAP.
Abstract 30
Methods in experimental gene transfer: How to get the gene of interest into a myocardium Myocardial gene therapy is a rapidly evolving field, so there are several different experimental procedures published in the literature describing different methods of how to get a gene of interest into myocardial cells.
We have injected ϳ500 hearts with recombinant viruses using three different methods. We used rats, rabbits, and pigs. Invasive surgical methods with an open abdominal or thoracal cavity are time consuming, high straining for the animals, and rarely used by our group.
We have achieved better results: (a) In the rat with a percutaneous direct injection under echocardiographic guidance. From the epigastric angle using a 21-gauge needle one can inject ϳ100 -150 L directly into the left ventricular inferior wall monitored by ultrasound with a 7.5-MHz probe. (b) In the rabbit, we prefer a transcoronary delivery using a JR-5F human diagnostic catheter introduced through a 5F sheath in the cartoid artery.
After placing the diagnostic catheter opposite the left coronary ostium, a 2.4F microferret catheter could be selectively introduced into the proximal circumflex artery and 1.0 -1.5 mL could be injected within 2 minutes. (c) In the pig, the procedure is comparable with the intracardiac catheter techniques developed for human use; we prefer to catheterize the left coronary artery with a 7F pigtail catheter introduced through a 7F caroid sheath.
The techniques are established for successful gene delivery to the heart in vivo.
Abstract 31
Protection of mice against leukemia after vaccination with dendritic cells loaded with apoptotic leukemia cells Dendritic cells (DC) are professional antigen (Ag)-presenting cells (APC) that need to be activated before they can function to initiate primary and secondary immune responses in vivo. In a murine model, we previously identified two populations of bone marrow (BM)-derived DC (cultured in the presence of granulocyte-macrophage colony-stimulating factor) that differ with regard to their level of expression of major histocompatibility complex (MHC) class II molecules. These populations, MHC class II high cells (high MHC class II expression) and MHC class II low cells (low MHC class II expression), likely correspond to different stages of DC maturation. We showed that MHC class II high cells were more efficient than MHC class II low cells in an antitumoral vaccination protocol. We used the murine L1210 B-lymphocytic leukemia genetically modified to express human CD4 (hCD4) on the cell surface as a model tumor-associated Ag (TAA). DC cultures were loaded with either purified soluble hCD4 protein (shCD4) or unfractionated L1210/hCD4 extracts and injected as vaccine into mice. The efficacy of these vaccinations was compared with that of vaccination with shCD4 protein emulsified in Freund's adjuvant (FA). We evaluated the immune responses generated after these vaccinal protocols and the survival rate of vaccinated mice subsequently challenged with a lethal injection of L1210/ hCD4 cells. Our results demonstrated that vaccination with shCD4 protein or tumor extract-loaded DC mainly generated a hCD4 Ag-specific cell-mediated cytotoxic immune response that was associated with a specific protection against leukemia. In contrast, vaccination with the protein emulsified in FA only generated potent humoral immune responses that were not protective against leukemia. Here we report that the immature DC population, low-expressing MHC class II molecules, can be activated in vitro by exogenous signals received from apoptotic leukemia cells. L1210/hCD4 leukemia cells were genetically modified to express the herpes simplex thymidine kinase (HSV-TK) "suicide" gene to induce their apoptotic death after treatment with ganciclovir (GCV). Apoptosis of L1210/hCD4/TK cells was detected by annexin-V fluorescein isothiocyanate flow cytometric analysis after 7 days of cell culture in the presence of 10 M GCV. The efficacy of phagocytosis of apoptotic cells by DC was also tested by flow cytometric analysis after a 24-hour coculture of previously labeled DC and apoptotic leukemia cells with green and red fluorochromes, respectively. Injected in vivo, these exogenous activated DC can function as natural adjuvants to stimulate a hCD4 Ag-specific cell-mediated cytotoxic immune response against leukemia development. Altogether, our data highlight the importance of characterizing in vitro-generated DC before use in immunotherapy and indicate that the unique property of loaded DC to trigger an anti-leukemic protective effect is mainly associated with cellular immune responses.
Abstract 32
Gene transfer of CD154 and interleukin-12 cDNA induces anti-leukemic immunity in a murine model of acute leukemia 
Object of Study:
Interleukin-12 (IL-12) is an essential cytokine for the generation of a T helper 1 (Th1) response, natural killer (NK) cells, and cytotoxic Tlymphocyte (CTL) stimulation. CD154 triggers CD40 on antigen-presenting cells, thus inducing antigen presentation to the immune system, production of IL-12, and also direct activation of NK cells. As IL-12 and CD154 share several pathways mediating the immune response, we investigated in an aggressive murine model of acute leukemia the relative anti-leukemic efficiency of IL-12, CD154, and IL-12ϩCD154 gene transfer.
Materials and Methods: DA1 IL-3-dependent cells were electroporated with a pCDNA3 expression vector carrying p210 BCR/ABL cDNA, and transduced cells were selected by culture in IL-3-free medium. Mice injected intraperitoneally (i.p.) with 10 4 -10 6 DA1-3b cells developed systemic lethal leukemia in 3-4 weeks with massive infiltration of bone marrow, spleen, and peripheral blood. Groups of C3H/HeJ mice were injected i.p. or intravenously with live or irradiated CD154 cells, IL-12 cells, and a mix of equal numbers of CD154-and IL-12-transduced DA1-3b cells. DA1-3b cells transfected with the pCDNA3.1/Zeo empty plasmid or wildtype DA1-3b cells were injected as controls.
Results: We observed that leukemic cells transduced by IL-12, CD154, and IL-12ϩCD154 showed reduced leukemogenicity. Vaccines with lethally irradiated IL-12, CD154, and CD154ϩIL-12 cells were able to cure mice injected previously with leukemic cells, but results were affected by the periodicity of immunization. No CTL activity against leukemic cells was observed, but NK cytotoxicity was enhanced in mice vaccinated with leukemic cells transduced by IL-12, CD154, and CD154ϩIL-12. We also observed that IL-12-transduced cells induced a Th1 profile of cytokine in CD4 ϩ T cells isolated from the spleens of vaccinated animals.
Conclusions: These results suggest that both CD154 and IL-12 gene transfer are able to induce anti-leukemic activity in a model of acute leukemia with equal efficiency; however, they are mediated by different mechanisms.
Abstract 33
Gene transfer of granulocyte-macrophage colony-stimulating factor, CD80, and CD154 cDNA enhances survival in a murine model of acute leukemia with persistence of minimal residual disease 
Object of Study:
Gene transfer of various cytokines and costimulatory molecules has been reported to induce a potent anti-leukemic immunity in murine models; however, the relative efficiency and possible synergistic effects between candidate genes have not been investigated extensively. We analyzed in a murine model of BCR/ABL acute leukemia whether gene transfer of CD154, CD80, or granulocyte-macrophage colony-stimulating factor (GM-CSF0 as single agent or a combination of CD154ϩGM-CSF, CD80ϩCD154, and GM-CSFϩCD80 in leukemic cells could enhance survival.
Materials and Methods: DA1 interleukin-3 (IL-3)-dependent cells were electroporated with a pCDNA3 expression vector carrying p210 BCR/ABL cDNA, and transduced cells were selected by culture in IL-3-free medium. Mice injected intraperitoneally (i.p.) with 10 4 -10 6 DA1-3b cells developed systemic lethal leukemia in 3-4 weeks with massive infiltration of bone marrow, spleen, and peripheral blood. Groups of C3H/HeJ mice were injected i.p. or intravenously with live or irradiated CD154-, CD80-, GM-CSF-, CD154ϩGM-CSF-, CD80ϩCD154-, and GM-CSFϩCD80-transduced DA1-3b cells. DA1-3b cells transfected with the pCDNA3.1/Zeo empty plasmid or wild-type DA1-3b cells were injected as controls. Minimal residual disease was investigated by two-step BCR/ABL reverse transcriptase-polymerase chain reaction (RT-PCR) using nested primers.
Results: We observed that CD154 gene transfer induced a marked inhibition of leukemogenicity, and also that CD154 and the combination of GM-CSF and CD80 gene transfer protected mice against subsequent challenge with leukemic cells and had a therapeutic effect on a pre-established leukemia disease. We also found minimal residual leukemic disease by RT-PCR up 6 -12 months in 0 -25% of animals injected with transduced leukemic cells and surviving to the challenge without evidence of disease, except in the control empty plasmid group, where very few mice survived to the challenge but all of those were positive by RT-PCR. Bladder malignancies are an attractive local target to evaluate p53 gene therapy. However, recombinant adenovirus (rAd)-mediated transgene expression in the bladder epithelium is poor. The reason for the low rAd accessibility may be the protective glycosamino-glycan (GAG) barrier of the luminal bladder epithelium. We added different concentrations of a detergent (Big Chap) to the rAd-formulation buffer to overcome this epithelial barrier and enhance rAd-mediated epithelial transgene expression. We tested gene transfer in rodents (in mice, in normal rats, and in Fisher rats with dibutylnitrosamine-induced bladder tumors) and in normal rabbits. The detergent formulation was administered intravesically together with rAd encoding the ␤-galactosidase (␤-gal) reporter gene (rAd-␤-gal). Transgene expression was evaluated at 48 hours posttreatment using whole-organ ␤-gal staining. Transgene expression was low in all animal models that received rAd-␤-gal formulated in a phosphate-buffered saline (PBS) buffer.
Conclusions
In sharp contrast, ␤-gal expression in the luminal epithelial surface was greatly enhanced in rodents and rabbits treated with rAd-␤-gal together with the enhancing agent. An impurity (Syn3) in Big Chap was identified as the active ingredient for enhancement of rAd-mediated transgene expression. Maximal effects were achieved with a formulation containing 1 mg/mL Syn3 and a rAd concentration of 1 ϫ 10 10 rAd particles/mL. Histological evaluation showed presence of ␤-gal in the transitional cells of the bladder epithelium in the normal bladders. Interestingly transgene expression was also enhanced using the Syn3 formulation in the superficial tumors known to have unregulated fibronectin receptors. Abrogation of GAG (protamine/urea pretreatment) did not enhance rAd-mediated transgene expression in rabbits, indicating that mechanisms other than GAG may be important. To further evaluate mechanisms, we transfected the bladder epithelium in vivo with fiberless rAd labeled with CY3 dye. Syn3 enhanced fiberless rAd uptake into the bladder epithelium, suggesting that enhancement is mediated by other mechanisms rather than via CAR. To confirm observations with the ␤-gal reporter, we tested the enhancement of transgene expression using the p53 tumor suppressor gene (rAd-p53). rAd-p53 was administered intravesically into normal rats or rats with bladder tumors. rAd-p53 transgene expression was tested by IHC in formalinfixed bladder sections. The Syn3 formulation clearly enhanced rAd-mediated p53 transgene expression compared with the PBS control.
These animal experiments demonstrate the potential to enhance rAd-mediated transgene expression in bladder models in vivo by a mechanism independent of CAR, fibronectin, or GAG. Experiments demonstrate the potential for local p53 gene therapy of superficial bladder cancer by selecting a formulation that enhances rAdmediated transgene expression in the bladder epithelium and in superficial bladder tumors.
Abstract 36
Differential cytotoxicity and bystander effect of the rabbit cytochrome P450 4B1 by two different prodrugs: Implications for pharmacogene therapy To date, only a few enzyme/prodrug systems have been evaluated for pharmacological gene therapy of cancer. In the present study, we further characterized the recently described prodrug-activating rabbit cytochrome P450 4B1 (CYP4B1) enzyme. Two different prodrugs are known for this enzyme, the substituted furane 4-ipomeanol (4-IM) and the aromatic amine 2-aminoanthracene (2-AA). For both prodrugs, we investigated the time course of cytotoxicity induction and the bystander effect by analyzing cell proliferation and viability after enzyme/prodrug treatment. Experiments were performed in rat 9L gliosarcoma cells stably expressing cyp4B1 (9L-4B1), and findings were compared with those obtained with the herpes simplex virus type 1 thymidine kinase (HSV-tk)/ganciclovir (GCV) system. CYP4B1-mediated activation of 2-AA is a very efficient system, requiring only 24 hours of prodrug treatment to kill 75% of the cells and to damage the residual cells lethally. In contrast, activation of 4-IM by CYP4B1 displayed comparable efficiency in cell killing, but residual cells regained proliferative activity after prodrug treatment was discontinued. HSV-tk/GCV therapy for 24 hours resulted in killing of only ϳ50% of the cells, but surviving cells were not viable. Differences were also found when evaluating the kinetics between 2-AA-and 4-IM-mediated cytotoxicity when survival of 9L-4B1 cells was determined after 1 day of additional incubation in normal medium. Whereas a significant cytotoxic effect of 2-AA was observed already after 15 minutes of prodrug exposure, similar cytotoxicity mediated by 4-IM was only achieved by exposure times of 1-2 hours. In the case of GCV treatment, pulses of 15 or 30 minutes were sufficient for significant killing of 9L-tk cells. In contrast to the HSV-tk/GCV system, only a moderate bystander effect was demonstrated in 9L/9L-4B1 cocultures upon treatment with 2-AA, but this effect was absent upon treatment with 4-IM. Bystander cell death mediated by 2-AA was dependent upon direct contact between transduced and nontransduced cells. The lack of a significant bystander effect with 4-IM may be of disadvantage in pharmacogene therapy of cancer. Nevertheless, the rapid induction of cytotoxicity without significant bystander cell death provides advantages for other applications of the CYP4B1 system such as gene marking experiments and gene replacement strategies. For both applications, combination with a prodrug activating system would increase the biological safety of the strategy, because unintentional side effects such as malignant transformation of normal cells could be controlled by prodrug treatment.
analyze the efficacy of suicide gene-modified cancer cells as an autologous tumor vaccine in a rat model mimicking a liver metastasis situation.
Materials and Methods:
We used a rat colon carcinoma cell line that, after subcapsular or intraportal injection in syngenic animals, generates single or multiple experimental liver metastasis, respectively. We have shown that introduction of a vector expressing the CD gene in this colon carcinoma cell line results in 5-FC sensitivity.
Results: 5-FC treatment induces regression of CDexpressing (CD ϩ ) tumors and renders treated animals resistant to subsequent challenge with wild-type (wt) tumor cells. More importantly, intrahepatic injection of CD ϩ tumor cells followed by 5-FC treatment induces total regression of a wt tumors pre-established in the controlateral liver lobe in 45% of the animals, evidencing the existence of a distant bystander effect. This vaccination significantly increases the survival of rats carrying single or multiple liver metastasis. The distant bystander effect is mediated by natural killer cells in our model and can also induce the regression of a wt liver tumor after subcutaneous vaccination.
Conclusions: These results suggest that suicide genemodified tumor cells can act as potent therapeutic vaccines against liver metastasis from colon carcinoma.
